Andrew Conway Ivy

Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA)

Retrieved on: 
Wednesday, February 15, 2023
Choroid, CNV, LTB4, Vance DeGeneres, Eye, Engineering, Drug discovery, Professor, ARVO, Intravitreal injection, Anxiety, VEGF, VEGF-A, C5, E pluribus unum, Tufts University School of Medicine, Leukotriene B4, Depression, Food, Risk, Choroidal neovascularization, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Endothelium, GMP, Leukotriene, Hot game, Geographic atrophy, American Society for Clinical Investigation, Blood, Therapy, Andrew Conway Ivy, Patient, Incidence, Retina, IVT, Visual system, AAO, Intellectual property, Kinetics, AMD, Inflammation, Medscape, PAS, PEGylation, Injection, McClard, Infection, IND, Pharmaceutical industry, Vaccine, Ophthalmology, Medicare, Akari

PASylation (PAS) technology is a biological alternative to the chemical conjugate polyethylene glycol (PEGylation) in the development of extended half-life recombinant protein therapeutics.

Key Points: 
  • PASylation (PAS) technology is a biological alternative to the chemical conjugate polyethylene glycol (PEGylation) in the development of extended half-life recombinant protein therapeutics.
  • Complement overactivation is a validated target and an important aspect in the pathophysiology of GA, while LTB4 may contribute to overexpression of VEGF-A, a key driver of CNV.
  • “Patients who have geographic atrophy also are at risk of developing an additional sight-threatening condition known as choroidal neovascularization or CNV, which presents more hurdles in the fight to preserve sight.
  • Medscape article on 24-month data presentation at AAO 2022 With Approval Pending, Pegcetacoplan Shows Mixed Results for Treating Geographic Atrophy https://www.medscape.com/viewarticle/981813#vp_2
    McClard CK, et al.